BetterLife Pharma — Investor Relations & Filings
BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing novel, patient-friendly compounds to treat neuro-psychiatric and neurological disorders, addressing significant unmet mental health needs. The company's core strategy involves revolutionizing brain health by producing non-hallucinogenic medicines. Its lead product candidate is 2-Bromo-LSD (BETR-001), a second-generation lysergic acid diethylamide (LSD) derivative. BETR-001 is designed to mimic the projected therapeutic properties of LSD, acting as a potent neuroplastogen, but without causing psychedelic effects or incurring the high regulatory hurdles associated with Schedule 1 controlled substances. BETR-001 is being developed as a potential therapy for debilitating conditions such as treatment-resistant depression, PTSD, anxiety, and cluster headaches.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2024-12-09 | English | |
| News release - English.pdf | 2024-10-23 | English | |
| Material change report - English.pdf | 2024-10-15 | English | |
| News release - English.pdf | 2024-07-17 | English | |
| Material change report - English.pdf | 2024-07-15 | English | |
| Report of exempt distribution (45-106F1) (amended).pdf | 2024-07-11 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 13762140 | News release - English.pdf | 2024-12-09 | English | ||
| 13754714 | News release - English.pdf | 2024-10-23 | English | ||
| 30871803 | Material change report - English.pdf | 2024-10-15 | English | ||
| 30346406 | News release - English.pdf | 2024-07-17 | English | ||
| 13743224 | Material change report - English.pdf | 2024-07-15 | English | ||
| 13742438 | Report of exempt distribution (45-106F1) (amended).pdf | 2024-07-11 | English | ||
| 13741528 | News release - English.pdf | 2024-07-03 | English | ||
| 30298826 | News release - English.pdf | 2024-06-26 | English | ||
| 13740109 | News release - English.pdf | 2024-06-14 | English | ||
| 30150019 | Notice of meeting - English.pdf | 2024-05-24 | English | ||
| 30150017 | Other.pdf | 2024-05-24 | English | ||
| 30150016 | Other.pdf | 2024-05-24 | English | ||
| 30150015 | Management information circular - English.pdf | 2024-05-24 | English | ||
| 30150014 | Form of proxy - English.pdf | 2024-05-24 | English | ||
| 30032973 | News release - English.pdf | 2024-05-14 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
BetterLife Pharma via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/46572/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=46572 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=46572 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=46572 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 46572}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BetterLife Pharma (id: 46572)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.